ライフサイエンスコーパス: androgen receptor

1 o, ZMIZ1 showed impaired coactivation of the androgen receptor.

2 required to make testosterone, nor a nuclear androgen receptor.

3 imately promote DNA double-strand breaks and androgen receptor activation in prostate epithelial cell

4 Androgen receptor activation is an important factor in t

5 cribe the Collaborative Modeling Project for Androgen Receptor Activity (CoMPARA) efforts, which foll

6 Ivermectin potentiated activity of anti-androgen receptor and anti-EGFR drugs in prostate and EG

7 activity that is concomitantly modulated by androgen receptor and by CCAAT/enhancer-binding protein

8 matin for steroid hormone receptors, such as androgen receptor and estrogen receptor(1-4), but mechan

9 ired for the transcriptional activity of the androgen receptor and its target gene expression.

10 e medium led to decreased expression of both androgen receptor and its target gene products, prostate

11 of predominantly luminal cells that express androgen receptor and require androgens for growth.

12 Herein, we investigated the role of androgen receptor and TES on the inflammatory response a

13 Notably, these brain regions are rich in androgen receptors and play a key role in modulating agg

14 AR (androgen receptor) and PKM2 (pyruvate kinase M2) have ke

15 al transcription factors, including p53, the androgen receptor, and NOTCH1.

16 FOXA1 in mediating oncogenesis driven by the androgen receptor, and provides mechanistic insights int

17 ty is repressed by the liganded estrogen and androgen receptors, and by the hypothalamic gonadotropin

18 ive tumours express luminal markers, such as androgen receptors, and have a lower proliferative activ

19 A weak androgen receptor antagonism was identified, whereas no

20 were divided in five groups (n = 10/group): androgen receptor antagonist (flutamide); estrogen recep

21 mide (MDV3100) is a potent second-generation androgen receptor antagonist approved for the treatment

22 The androgen receptor antagonist enzalutamide was associated

23 fically, we bilaterally implanted the potent androgen receptor antagonist flutamide in two key brain

24 The mineralocorticoid and androgen receptor antagonist spironolactone (SP) was rec

25 Darolutamide is a structurally unique androgen-receptor antagonist that is under development f

26 tate cancer growth alone and in synergy with androgen-receptor antagonist treatment in vivo.

27 Advanced prostate cancers resistant to androgen receptor antagonists are still susceptible to n

28 Treatment with estrogen and androgen receptor antagonists had opposite effects on Le

29 positive outcomes for non-metastatic PC with androgen receptor antagonists, respectively.

30 cit immune response, and the presence of the androgen receptor AR-V4 and -V7 isoforms in all NCI-60 t

31 Androgen receptor (AR) action is a hallmark of prostate

32 Androgen receptor (AR) activation is critical for prosta

33 ation of mechanisms underlying the increased androgen receptor (AR) activity and subsequent developme

34 Suppression of androgen receptor (AR) activity in prostate cancer by an

35 ought to reconcile the clear contribution of androgen receptor (AR) activity that has been establishe

36 drogens control transcription by stimulating androgen receptor (AR) activity, yet also control pre-mR

37 ant impact on progesterone receptor (PR) and androgen receptor (AR) activity.

38 Sustained reliance on androgen receptor (AR) after failure of AR-targeting and

39 ens in muscle, and that intervention with an androgen receptor (AR) agonist will reverse musculoskele

40 TSPY and TSPX competitively bind to the androgen receptor (AR) and AR variants, such as AR-V7, a

41 Endogenous TET2 bound the androgen receptor (AR) and AR-coactivator proteins in LN

42 riple-negative breast cancers (TNBC) express androgen receptor (AR) and are potentially responsive to

43 ctivation of transcription factors including androgen receptor (AR) and c-Myc.

44 BRD9 interacts with androgen receptor (AR) and CCCTC-binding factor (CTCF),

45 The androgen receptor (ar) and cytochrome P450 1A genes were

46 ells, most prostate cancer cells express the androgen receptor (AR) and depend on androgens for their

47 link ligand chemical structures to MIEs for androgen receptor (AR) and glucocorticoid receptor (GR)

48 ed LNCaP proliferation, along with decreased androgen receptor (AR) and increased Nkx3.1 cellular exp

49 tochondrial deacetylase sirtuin 3 (SIRT3) by androgen receptor (AR) and its coregulator steroid recep

50 prostate-specific enhancers enriched for the androgen receptor (AR) and lineage-specific cofactors.

51 r develops very slowly in most men, with the androgen receptor (AR) and MYC transcription factors amo

52 ontext, CCN3 has been shown to sequester the androgen receptor (AR) and suppress AR signaling.

53 at the bulk of prostate cancer cells express androgen receptor (AR) and that androgens are required f

54 Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) pr

55 The androgen receptor (AR) antagonist enzalutamide is a Food

56 s developed resistance to the new-generation androgen receptor (AR) antagonist enzalutamide is a leth

57 The androgen receptor (AR) antagonist enzalutamide is one of

58 Enzalutamide, a second-generation androgen receptor (AR) antagonist, has demonstrated clin

59 -C in androgen-dependent PC cells suppresses androgen receptor (AR) axis signaling and induces the ne

60 he lncRNA-p21 transcription via altering the androgen receptor (AR) binding to different androgen-res

61 nomously activates Nkx3.1 expression through androgen receptor (AR) binding to the 11-kb region in bo

62 Androgen receptor (AR) blockade and metabolic stress ind

63 zalutamide (Enz) can occur through bypass of androgen receptor (AR) blockade by the glucocorticoid re

64 ponsive to sex hormones, with enhancement by androgen receptor (AR) but suppression by estrogen recep

65 Inhibition of the androgen receptor (AR) by second-generation anti-androge

66 Alteration to the expression and activity of androgen receptor (AR) coregulators in prostate cancer i

67 Nuclear localization of androgen receptor (AR) directs transcriptional regulatio

68 ral androgen biosynthesis and an increase in androgen receptor (AR) expression.

69 ssion, which is largely driven by functional Androgen Receptor (AR) expression.

70 as been principally linked to suppression of androgen receptor (AR) function.

71 While HOXB13 regulates Androgen Receptor (AR) functions in a context dependent

72 chaperones such as Hsp40 and Hsp70 hold the androgen receptor (AR) in an inactive conformation.

73 We focused on the function of the androgen receptor (AR) in HCC and tried to find new trea

74 igenetically activating transcription of the androgen receptor (AR) in prostate cancer cells.

75 The crucial role of androgen receptor (AR) in prostate cancer development is

76 This study investigates the role of androgen receptor (AR) in regulating CXCR7.

77 e of this work was to evaluate the effect of androgen receptor (AR) inhibition on prostate-specific m

78 Androgen receptor (AR) inhibitors represent the mainstay

79 The androgen receptor (AR) is a critical therapeutic target

80 Androgen receptor (AR) is a ligand-activated transcripti

81 The androgen receptor (AR) is a target of interest for endoc

82 Androgen receptor (AR) is a transcriptional activator th

83 The androgen receptor (AR) is a type I nuclear hormone recep

84 uman epidermal growth factor receptor 2, the androgen receptor (AR) is also a potential drug target i

85 F-1) domain located in the N-terminus of the androgen receptor (AR) is an attractive therapeutic alte

86 Genomic amplification of the androgen receptor (AR) is an established mechanism of an

87 The androgen receptor (AR) is critical for the progression o

88 such as ERalpha, the activation function of androgen receptor (AR) is largely dependent on its ligan

89 ighly expressed in cancer cells in which the androgen receptor (AR) is not detected (AR-), whereas th

90 The androgen receptor (AR) is often activated in prostate ca

91 The androgen receptor (AR) is required for prostate cancer (

92 The androgen receptor (AR) is the main driver of prostate ca

93 Inhibition of the androgen receptor (AR) is the main strategy to treat adv

94 The androgen receptor (AR) is the major driver of prostate c

95 The androgen receptor (AR) is thought to control the express

96 The androgen receptor (AR) is tightly linked to prostate can

97 Prostate cancer (CaP) driven by androgen receptor (AR) is treated with androgen deprivat

98 Androgen receptor (AR) is widely expressed in different

99 Androgen receptor (AR) is widely expressed throughout th

100 Unexpectedly, TRX1 inhibition also elevates androgen receptor (AR) levels under AD, and AR depletion

101 that the chromatin structure surrounding the androgen receptor (AR) locus is altered in the prostate

102 Aberrant activation of the androgen receptor (AR) may play a critical role in castr

103 Androgen receptor (AR) mediates the growth of prostate c

104 Although more than 1,000 androgen receptor (AR) mutations have been identified an

105 Since testosterone can work directly via the androgen receptor (AR) or indirectly via the estrogen re

106 Many pesticides can antagonize the androgen receptor (AR) or inhibit androgen synthesis in

107 ased on the expression of well-characterized androgen receptor (AR) or neuroendocrine (NE) genes: (i)

108 e-genome duplication, A. burtoni possess two androgen receptor (AR) paralogs, ARalpha and ARbeta, pro

109 800 chemicals for estrogen receptor (ER) and androgen receptor (AR) pathway bioactivity.

110 cancer (PCa) cells heavily rely on an active androgen receptor (AR) pathway for their survival.

111 The androgen receptor (AR) pathway is emerging as a potentia

112 onal targets of E2F, and identified that the androgen receptor (AR) played a critical role in the tra

113 Recent studies indicated that the androgen receptor (AR) plays important roles in modulati

114 We were also able to identify the androgen receptor (AR) point mutation T878A from 7.5 mL

115 d 100 cases of human melanoma and found that androgen receptor (AR) positive melanoma patients have w

116 While androgen receptor (AR) primarily binds to a putative CHP

117 Androgen receptor (AR) protein levels were increased in

118 Here, the authors show that androgen receptor (AR) regulates HR and AR inhibition ac

119 The androgen receptor (AR) regulates male sexual development

120 eading cause of cancer death in men, and the androgen receptor (AR) represents the primary target for

121 and P63 and loss in DACH1 and PURalpha, two androgen receptor (AR) repressors.

122 (polyQ) tract polymorphism within the human androgen receptor (AR) shows population heterogeneity.

123 Loss of androgen receptor (AR) signaling dependence occurs in ap

124 of the disease, is characterized by loss of androgen receptor (AR) signaling during neuroendocrine t

125 ostate cancer (PC) is initially dependent on androgen receptor (AR) signaling for survival and growth

126 ate cancer (PCa), leading to reactivation of androgen receptor (AR) signaling in a hormone-refractory

127 Androgen receptor (AR) signaling in Sertoli cells is kno

128 Androgen receptor (AR) signaling is a distinctive featur

129 Androgen receptor (AR) signaling is a key driver of pros

130 Androgen receptor (AR) signaling is central to PCa and P

131 cancerous phenotype and maintains downstream androgen receptor (AR) signaling pathways.

132 (mCRPC) develops resistance to inhibitors of androgen receptor (AR) signaling through a variety of me

133 cancer is characterized by a dependence upon androgen receptor (AR) signaling, and androgen deprivati

134 Initially CRPC remains dependent on androgen receptor (AR) signaling, often through increase

135 castration resistant prostate cancers become androgen receptor (AR) signaling-independent and develop

136 ced prostate cancer therapies aim to inhibit androgen receptor (AR) signaling.

137 e hormonal treatments due to reactivation of androgen receptor (AR) signaling.

138 imens for prostate cancer focus on targeting androgen receptor (AR) signaling.

139 Androgen receptor (AR) signalling is a key prostate canc

140 Androgen receptor (AR) signalling is essential in nearly

141 Androgen receptor (AR) splice variants including AR-V7 f

142 Enz resistance that may involve inducing the androgen receptor (AR) splicing variant 7 (ARv7).

143 ll growth at least in part through c-Myc and androgen receptor (AR) suppression.

144 DECR1 is a negatively-regulated androgen receptor (AR) target gene and, therefore, may p

145 We show that PARG is a direct androgen receptor (AR) target gene.

146 Resistance to androgen receptor (AR) targeting therapeutics in prostat

147 Androgen signals through androgen receptor (AR) to influence prostate development

148 we demonstrate a direct requirement for the androgen receptor (AR) to maintain HR gene expression an

149 The androgen receptor (AR) transcription factor is a master

150 2 (CHK2) is a critical negative regulator of androgen receptor (AR) transcriptional activity, prostat

151 ivities of transcription factors such as the androgen receptor (AR) underpin prostate cancer developm

152 and RNA-based genomic alterations, including androgen receptor (AR) variant expression, AR transcript

153 generation of constitutively active forms of androgen receptor (AR) variants including AR-V7 plays an

154 (PCa) genomic data, and found that BMI1 and androgen receptor (AR) were positively correlated, sugge

155 denced by the dependency of PCa cells on the androgen receptor (AR), a prostate master transcription

156 ILC2Ps express the androgen receptor (AR), and AR signaling inhibits their

157 scovery of highly potent PROTAC degraders of androgen receptor (AR), as exemplified by compound 34 (A

158 teins elevated in mutant ER cells, including androgen receptor (AR), chitinase-3-like protein 1 (CHI3

159 Androgen receptor (AR), is a transcription factor and a

160 ent tumors typically remain dependent on the androgen receptor (AR), non-AR-driven tumors that also e

161 sor by targeting several proteins, including androgen receptor (AR), steroid receptor coactivator 3 (

162 xpress estrogen receptor alpha (ERalpha) and androgen receptor (AR), suggesting changing levels of go

163 As androgens mediate their actions via the androgen receptor (AR), we combined a mouse model of dih

164 s binding of beta-catenin to the promoter of androgen receptor (AR), which leads to increased express

165 drug enzalutamide by a phenotypic shift from androgen receptor (AR)-dependent luminal epithelial cell

166 Emergence of an aggressive androgen receptor (AR)-independent neuroendocrine prosta

167 TEFb (CDK9/cyclin T) plays a central role in androgen receptor (AR)-mediated transactivation by phosp

168 ession of prostate cancer to a highly lethal androgen receptor (AR)-negative phenotype.

169 nce with the widespread use of highly potent androgen receptor (AR)-pathway inhibitors (APIs) such as

170 s and lymph node metastasis showing that the androgen receptor (AR)-positive ccRCC may prefer to meta

171 DOT1L selectively impaired the viability of androgen receptor (AR)-positive PCa cells and organoids,

172 tibody that internalizes in cells expressing androgen receptor (AR)-regulated prostate-specific enzym

173 d activation of progenitor genes, as well as androgen receptor (AR)-target genes.

174 Resistance to androgen receptor (AR)-targeted therapies in prostate ca

175 Despite the clinical success of Androgen Receptor (AR)-targeted therapies, reactivation

176 ted from the key prostate cancer driver gene-androgen receptor (AR).

177 ucleotide expansion in the gene encoding the androgen receptor (AR).

178 ed by polyglutamine (polyQ) expansion in the androgen receptor (AR).

179 h has similar DNA-binding specificity to the androgen receptor (AR).

180 cer is driven by androgen stimulation of the androgen receptor (AR).

181 a polyglutamine tract in the gene coding for androgen receptor (AR).

182 17 inhibitors can interact directly with the androgen receptor (AR).

183 rally caused by augmented signaling from the androgen receptor (AR).

184 ostate cancer that expressed the full-length androgen receptor (AR).

185 the strict androgen-dependent regulation of androgen receptor (AR): binding of androgen induces stru

186 Increased expression of the full-length androgen receptor (AR-FL) and AR splice variants (AR-Vs)

187 ations with disease progression, full-length androgen receptor (AR-FL) expression, response to therap

188 ee such master regulators (FOXA1, NKX3.1 and androgen receptor, AR) in a primed conversion strategy s

189 rogenetic alopecia revealed that next to the androgen receptor as well the retinoid receptor and part

190 our results identify ALK5 and non-canonical androgen receptors as potential therapeutic targets for

191 ing cytotoxic drugs and agents targeting the androgen receptor axis, immune checkpoint receptors or D

192 ng a 6-fold difference in log-probability of androgen receptor binding at the variant rs2680708 (17q2

193 ion signature, which revealed enrichment for androgen receptor binding sequences and hypomethylation

194 that genes in this factor were enriched for androgen receptor binding sites.

195 ugh FOXA1, LSD1 inhibition broadly disrupted androgen-receptor binding and its transcriptional output

196 Surprisingly, androgen receptor controls a splicing program distinct f

197 aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists

198 ies II and III) were discovered as selective androgen receptor degraders (SARDs).

199 rowth and motility, a known signal to bypass androgen receptor dependence.

200 n disease onset and progression through both androgen receptor-dependent and androgen receptor-indepe

201 h was abrogated by dihydrotestosterone in an androgen receptor-dependent manner.

202 However, inhibition of androgen receptor did not lead to increased phosphorylat

203 tein expression levels of AROM, estrogen and androgen receptors did not differ between males and fema

204 ed after one to two lines of next-generation androgen receptor-directed therapy and one taxane-based

205 the steroid nuclear hormone receptor family (androgen receptor, estrogen receptor alpha, glucocortico

206 Clinically relevant Ezh2 inhibitors restore androgen receptor expression and sensitivity to antiandr

207 like subtypes were associated with increased androgen receptor expression and signaling, only luminal

208 We found androgen receptor expression in male and female genital

209 vides a noninvasive method for assessment of androgen receptor expression in patients with metastatic

210 Here the authors show how androgen receptor expression influences the metastatic r

211 With no or a very low level of androgen receptor expression, the tumor cells were resis

212 prescribed for CRPC which works by blocking androgen receptor function.

213 sults from a CAG repeat expansion within the androgen receptor gene (AR).

214 this group, expression of glucocorticoid and androgen receptor genes explained the most variance in t

215 androgen deprivation, downregulation of the androgen receptor -> phosphatidylinositol-3-kinase -> Ak

216 creasingly effective therapies targeting the androgen receptor have paradoxically promoted the incide

217 o those in glucocorticoid receptor (HPA) and androgen receptor (HPG) gene expression.

218 ernatant induce nuclear translocation of the androgen receptor in female genital skin primary culture

219 Deletion of androgen receptor in GHRH neurons only delayed female pu

220 igenic potential of Src and its synergy with androgen receptor in mediating tumor invasion.

221 ovel mouse model with a specific ablation of androgen receptor in the adrenal cortex with or without

222 f PPARGC1a in the epithelial compartment and androgen receptor in the dermal papilla of miniaturized

223 A9) was recently characterized as a membrane androgen receptor in various teleost and mammalian cell

224 ivation by PrCa master-regulators (including androgen receptor) in Position Weight Matrix, Chip-Seq,

225 through both androgen receptor-dependent and androgen receptor-independent mechanisms.

226 t ERG, through its physical interaction with androgen receptor, induces AR aggregation and endoplasmi

227 rase-1 plus androgen receptor is superior to androgen receptor inhibition in metastatic castration-re

228 xpression, the tumor cells were resistant to androgen receptor inhibition.

229 ndrogen deprivation mimicking castration and androgen receptor inhibition.

230 nhanced neuritogenesis in the presence of an androgen receptor inhibitor to the extent seen in ED pep

231 Darolutamide is a structurally distinct androgen-receptor inhibitor that is approved for the tre

232 Enzalutamide, an androgen-receptor inhibitor, has been associated with im

233 argeting poly (ADP-ribose) polymerase-1 plus androgen receptor is superior to androgen receptor inhib

234 e-cell RNAseq (scRNAseq) in the Sertoli-cell androgen receptor knockout (SCARKO) mutant and control m

235 nst MDA-MB-453 cells, a model of the luminal androgen receptor (LAR) subtype of TNBC.

236 ur transcriptome-based subtypes: (1) luminal androgen receptor (LAR), (2) immunomodulatory, (3) basal

237 ession alterations, and were convergent onto androgen receptor-mediated signaling pathways.

238 asodilatation in AE-PCOS is a consequence of androgen receptor-mediated, suppressed ET(B) R-stimulate

239 describes different effects of the selective androgen receptor modulator (SARM) nandrolone phenylprop

240 only 23 (52%) contained 1 or more selective androgen receptor modulators (Ostarine, LGD-4033, or And

241 lty, we describe a novel series of selective androgen receptor modulators (SARMs).

242 d and sold through the internet as selective androgen receptor modulators and compare the analyzed co

243 Only 52% contained selective androgen receptor modulators and many were inaccurately

244 nalyses of 44 products marketed as selective androgen receptor modulators and sold via the internet,

245 g 44 products marketed and sold as selective androgen receptor modulators, only 23 (52%) contained 1

246 the increasing use of nonsteroidal selective androgen receptor modulators, which have not been approv

247 Products marketed and sold as selective androgen receptor modulators.

248 sers to identify suppliers selling selective androgen receptor modulators.

249 each product marketed and sold as selective androgen receptor modulators.

250 While androgens may function via nuclear androgen receptor (nAR) to increase bladder cancer (BCa)

251 t engagement, evidenced by decreased percent androgen receptor nuclear localization (%ARNL) and incre

252 ter three cycles of chemotherapy (n = 16) or androgen receptor pathway inhibitors (n = 40).

253 was found to be independent of the canonical androgen receptor pathway.

254 NA damage/replication stress response, TP53, androgen receptor, phosphatidylinositol-3-kinase/AKT, an

255 lling of key regulatory cascades such as the androgen receptor, PI3K-AKT or GATA2-dependent pathways,

256 ding several haematological malignancies and androgen receptor-positive prostate cancer.

257 quency, and strongly transactivate a luminal androgen-receptor program of prostate oncogenesis.

258 parg mRNA expression and increased placental androgen receptor protein expression.

259 in prostate adenocarcinoma are driven by the androgen receptor, providing opportunities for functiona

260 arms showed comparable levels of ERG, PTEN, androgen receptor PSA, and glucocorticoid receptor expre

261 We have previously shown that miR-32 is an androgen receptor-regulated miRNA overexpressed in castr

262 -independent phenotypes by altering the AP-1/androgen receptor regulatory circuit in PCa cells.

263 n males than in females due to the different androgen receptor signaling but the molecular mechanisms

264 ies showed regulation of DNA repair genes by androgen receptor signaling in prostate cancers.

265 There is mounting evidence of androgen receptor signaling inducing genome instability

266 ts treated with a first-line next-generation androgen receptor signaling inhibitor (ARSI; abiraterone

267 ply a marker of resistance to 2nd-generation androgen receptor signaling inhibitors (ARSi) like abira

268 ated with better OS in patients treated with androgen receptor signaling inhibitors (ARSI), whereas h

269 rall survival times in patients treated with androgen receptor signaling inhibitors and taxanes.

270 and genetic experiments revealed that intact androgen receptor signaling is necessary for androgen's

271 R1 levels increase in response to suppressed androgen receptor signaling or loss of the tumor suppres

272 ncometabolite, can directly regulate nuclear androgen receptor signaling to drive tumorigenesis, ther

273 t SPOP mutation activates both PI3K/mTOR and androgen receptor signaling, effectively uncoupling the

274 nd candidate resistance mechanisms including androgen receptor signaling, mucin overexpression and an

275 gnaling may be activated upon suppression of androgen receptor signaling.

276 somatic genomic events in the context of the androgen receptor signaling.

277 MR, and CCNB1) and decreased dependence upon androgen receptor signaling.

278 on of markers associated with proliferation, androgen-receptor signaling, and hypoxia was assessed by

279 strointestinal-lineage genes, independent of androgen-receptor signaling.

280 The blockage of androgen receptor significantly increased radiographic b

281 Expression of the androgen receptor splice variant 7 (AR-V7) is frequently

282 Androgen receptor splice variant 7 (AR-V7) results in a

283 demonstrated that the constitutively active androgen receptor splice variant-7 (AR-V7) associates wi

284 The role of truncated androgen receptor splice variant-7 (AR-V7) in prostate c

285 We reported previously that the detection of androgen receptor splice variant-7 (AR-V7) mRNA in circu

286 Treatment-refractory, constitutively active androgen receptor splice variants promote hepatocellular

287 of cancer-specific transcripts including the androgen-receptor splice variant 7 in a cohort of prosta

288 ls to be AE1/AE3, CK7, GCDFP-15, E-cadherin, androgen receptor stain and GATA3 positive.

289 sitivity and the second documented case with androgen receptor stain positivity.

290 Molecular analyses implicate aberrant androgen receptor stimulation, biliary acid disturbances

291 and its transcriptional activity through the androgen receptor-STK4/MST1-protein phosphatase 2A axis,

292 Androgen receptor-targeted therapies, including AR agoni

293 itaxel (n = 22); 44.4% received prior potent androgen receptor-targeted therapy.

294 Androgen receptor-targeted treatments for breast cancer

295 ich forms a transcriptional complex with the androgen receptor to regulate target genes.

296 e Cancer Genome Atlas revealed that YAP1 and androgen receptor transcript levels correlate with each

297 A-485 inhibited the androgen receptor transcriptional program in both androg

298 e prostate cells, including expansion of the androgen receptor transcriptional repertoire, and ERF ha

299 d response to therapy had elevated levels of androgen receptor variant 7 (ARV7) and the mesenchymal m

300 Androgen receptor variants (AR-Vs) provide a mechanism o